Article
Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite Leishmania donovani.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 18 May 2021
Potvin Jade-Eva, Leprohon Philippe, Queffeulou Marine, Sundar Shyam, Ouellette Marc
Abstract excerpt
BACKGROUND: Antimonial drugs have long been the mainstay to treat visceral leishmaniasis. Their use has been discontinued in the Indian subcontinent because of drug resistance, but they are still clinically useful elsewhere. The goal of this study was to find markers of antimony resistance in Leishmania donovani clinical isolates and validate experimentally their role in resistance. METHODS: The genomes of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
